Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6806094 | 1.00 | TUBB1 (0.58) | TUBB1CTSLCTSBCTSSCTSK | |
| SCHEMBL6801142 | 0.96 | TUBB1 (0.63) | TUBB1CTSLCTSBCTSSCTSK | |
| SCHEMBL6801150 | 0.96 | TUBB1 (0.63) | TUBB1CTSLCTSBCTSSCTSK | |
| Trifluoroacetic Acid SCHEMBL6806056 | 0.92 | TUBB1 (0.63) | TUBB1CTSLCTSBCTSSCTSK | |
| Taltobulin SCHEMBL30483111 | 0.88 | TUBB1 (0.74) | TUBB1 | |
| Trifluoroacetic Acid SCHEMBL6671228 | 0.88 | TUBB1 (0.64) | TUBB1CTSLCTSBCTSSCTSK | |
| Trifluoroacetic Acid SCHEMBL6671230 | 0.88 | TUBB1 (0.64) | TUBB1CTSLCTSBCTSSCTSK | |
| SCHEMBL6800265 | 0.88 | TUBB1 (0.68) | TUBB1CTSLCTSBCTSSCTSK | |
| SCHEMBL6671030 | 0.88 | TUBB1 (0.68) | TUBB1CTSLCTSBCTSSCTSK | |
| Trifluoroacetic Acid SCHEMBL6806174 | 0.87 | TUBB1 (0.58) | TUBB1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | TUBB1 199/4885CTSL 2059/4885CTSB 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.